Law.com Radar detected an uptick in securities cases centering on the COVID-19 pandemic. Eight federal lawsuits were surfaced ...

As 2025 unfolds, changes across the patent landscape are unfolding. From agency leadership transitions to proposed legislation and evolving ...

LIST wins contract to conduct feasibility study on enriching uranium to empower Department of the Air Force’s global operations Oak Ridge, ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

The U.S. patent system feels to me an awful lot like the Titanic right now. The Trump Administration is withdrawing employment offers to patent examiners and firing examiners still within their ...

QIAGEN has filed a lawsuit against bioMérieux in the German Unified Patent Court to protect its QuantiFERON technology, specifically its Europea ...

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A.

According to a recent market analysis, startups with patents and trademarks are 10 ... costs and accelerate timelines. HBR’s analysis particularly notes how important the latter is, as not ...

In 2024, the U.S. Food and Drug Administration (FDA) indicated that ELPIS II is a pivotal trial and, if it demonstrates sufficient evidence of efficacy, it would be acceptable for a Biologics License ...